Ischemic and hemorrhagic abdominal complications in COVID-19 patients: experience from the first Italian wave

Table 3 Clinical and laboratory parameters according to patient’s comorbidities (cardiovascular and no cardiovascular)

	Cardiovascular comorbidities	No cardiovascular comorbidities	p
	23	7	p
Leucocytes (10⁹/L)	13.2 (10.2–21.6)	13.6 (10.7–17.9)	0.848
Neutrophils (10⁹/L)	11.8 (7.8–19.7)	12.4 (9.8–15.7)	0.962
Lymphocytes (10⁹/L)	1.4 (0.8–1.6)	1.3 (0.6–9.1)	0.848
Platelets (10⁹/L)	251 (190–356)	140 (54–260)	0.158
PT-INR	1.17 (1.08–1.58)	1.26 (1.08–1.58)	0.823
aPTT	1.20 (0.99–1.61)	1.37 (1.19–2.13)	0.181
d-Dimer (ng/mL)	3063 (1184–7882)	3000 (1612–6292)	0.999
Fibrinogen (mg/dL)	586 (352–757)	310 (199–395)	0.047
CRP (mg/dL)	9.6 (5.1–22.6)	4.7 (2.7–9.5)	0.077
IL-6 (pg/mL)^a	106 (45–424)	332 (63-^b)	0.517
Procalcitonin (μg/mL)	0.43 (0.18–11.9)	0.35 (0.12–1.79)	0.444

Data are shown as median (25–75th percentile range). p is the statistical significance by Mann–Whitney test between groups
PT-INR prothrombin time international normalized ratio, aPPT activated partial thromboplastin time, CRP C-reactive protein, IL-6 interleukin-6
^aIL-6 measurement was available only for 10 patients (3 in the group without cardiovascular comorbidity and 7 in the group with cardiovascular comorbidity)
^b75th value not available

ISSN: 2047-783X